Liveyon uses only umbilical cord-derived regenerative medicine products. This causes no pain for the patient as there is no extraction or procedure required to obtain the stem cell-based product. Moreover, the product contains no known proteins that can cause rejection in your patient. Research has shown that umbilical cord-derived stem cells are not susceptible to malignant transformation in a serum-free medium, making them safe for therapeutic use in patients.
Our regenerative medicine product is produced in a cGMP lab that receives all cord tissue/blood donations from hospitals directly to the facility, which guarantees minimal handling and a lower risk of cell loss or contamination. Our regenerative medicine product is produced in compliance with FDA cGMP (Current Good Manufacturing Practice) and GTP (Good Tissue Practices) standards, which assures you the end user quality and safety in our product. Most importantly, our regenerative medicine product is minimally manipulated preserving its natural healing properties.
Liveyon’s regenerative medicine product is easily shipped and once delivered yields consistent concentrations allowing for multiple administrations in uniform, high-cell-count doses. Patients can enjoy safe, non-surgical treatments in the time it would take them for a traditional office visit.
Liveyon’s ReGen® Series contains stem cells. Our characterized product contains mesenchymal stem cells (MSCs). These are defined by the stem cell marker CD90. Moreover, they are negative for HLA-DR which helps you feel comfortable that your patient will not have any negative reactions to the product.